References
- Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340–8
- Mardiak J, Salek T, Sycova-Mila Z, Obertova J, Reckova M, Mego M, et al. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study. Neoplasma 2007; 54: 240–5
- Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25: 708–14
- Sonpavde G, Hutson TE, Roth BJ. Management of recurrent testicular germ cell tumors. Oncologist 2007; 12: 51–61
- Fung MK, Cheung HW, Ling MT, Cheung AL, Wong YC, Wang X. Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells. Br J Cancer 2006; 95: 475–84
- Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S, Ehrsson H. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 2003; 51: 36–42
- Balazova E, Hrubisko M, Ujhazy V. In vivo and in vitro effectivity of some platinum complexes. Neoplasma 1984; 31: 641–7
- Estrem SA, Babin RW, Ryu JH, Moore KC. Cis-diamminedichloroplatinum (II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg 1981; 89: 638–45
- Anniko M, Sobin A. Cisplatin: evaluation of its ototoxic potential. Am J Otolaryngol 1986; 7: 276–93
- Thomas JP, Lautermann J, Liedert B, Seiler F, Thomale J. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol 2006; 70: 23–9
- Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 2006; 12: 5817–25
- Blakley BW, Cohen JI, Doolittle ND, Muldoon LL, Campbell KC, Dickey DT, et al. Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope 2002; 112: 1997–2001
- Lutz T, Nivel P, Schmidt B. Whole blood analysis by ICP-MS. Application of plasma source mass spectrometry, H Holland, A Eaton. Royal Society of Chemistry, Cambridge 1991; 96–100
- Sun X, Ting W, Ziesel S, Janghorbani M. Accurate measurement of stable isotopes of lithium by inductively coupled plasma mass spectrometry. Analyst 1987; 112: 1223–8
- Hanada T, Isobe H, Saitoh T, Ogura S, Saito K, Kawakami Y. Inductively coupled plasma mass spectrometry for the determination of platinum accumulation in human non small cell lung cancer lines. Int J Clin Oncol 1998; 3: 98–101
- Thalmann I. Inner ear proteomics: a fad or hear to stay. Brain Res 2006; 1091: 103–12
- Coling D, Ding D, Young R, Lis M, Stofko E, Blumenthal K, et al. Proteomic analysis of cisplatin-induced cochlear damage: methods and early changes in protein expression. Hear Res 2007; 226: 140–56
- Ramirez-Camacho R, Citores MJ, Trinidad A, Verdaguer JM, Garcia-Berrocal JR, Marero AM, et al. HSP-70 as a nonspecific early marker in cisplatin ototoxicity. Acta Otolaryngol 2007; 127: 564–7
- Ramirez-Camacho R, Garcia-Berrocal JR, Bujan J, Martin-Marero A, Trinidad A. Supporting cells as a target of cisplatin-induced inner ear damage: therapeutic implications. Laryngoscope 2004; 114: 533–7
- El-Kareh A, Secomb T. A mathematical model for cisplatin cellular pharmacodynamics. Neoplasia 2003; 5: 161–9
- Pascoe J, Roberts J. Interactions between mammalian cell DNA and inorganic platinum compounds: I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds. Biochem Pharmacol 1974; 23: 1359–65